Spyre Therapeutics, Inc. · NASDAQ:SYRE
Venrock Healthcare Capital Partners III, L.P.'s stake in Spyre Therapeutics, Inc. fell to 4.60% (Schedule 13G/A)
Event Dec 31, 2024 · Filed Feb 14, 2025
Venrock Healthcare Capital Partners III, L.P.'s stake in Spyre Therapeutics, Inc. fell to 4.60%, 2,685,448 shares, as a passive investor on Dec 31, 2024. Filed Feb 14, 2025 (Schedule 13G/A).
- Stake
- 4.60%
- Shares
- 2,685,448
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 4.60% | 2,685,448 |
| VHCP Co-Investment Holdings III, LLC | 4.60% | 2,685,448 |
| Venrock Healthcare Capital Partners EG, L.P. | 4.60% | 2,685,448 |
| VHCP Management III, LLC | 4.60% | 2,685,448 |
| VHCP Management EG, LLC | 4.60% | 2,685,448 |
| Nimish Shah | 4.60% | 2,685,448 |
| Bong Y Koh | 4.60% | 2,685,448 |
Source
Related
- Spyre Therapeutics, Inc.
- Venrock Healthcare Capital Partners III, L.P.
- Spyre Therapeutics, Inc. shareholders
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026